BIO-key International closed Tuesday at $4.69, down 9% on the day and 26% over the past week — and the move is not just a bad tape story.
The proximate cause is a pair of corporate developments that landed in quick succession. On April 22, Nasdaq issued a non-compliance notice tied to a delayed Form 10-K filing. Days later, on April 28, the company executed a 1-for-10 reverse stock split following stockholder approval — a move typically associated with companies scrambling to stay above exchange minimum price thresholds. That the split landed the same week as a compliance notice sharpens the concern. The next scheduled earnings event is May 15, but investors have little financial visibility with the annual report still outstanding.
Short interest tells a story of rapid retreat rather than building pressure. At just over 1% of the free float, short positioning is thin and falling fast — down 51% over the week to roughly 119,000 shares. Despite that, the borrow market is still elevated: cost to borrow runs near 40% annualised, which is expensive for a name with such modest short interest. Availability is ample at around 533% of current short interest, meaning supply of lendable shares is not a constraint. The days-to-cover ratio ranks in the 94th percentile of all stocks, reflecting how thinly traded the name is relative to whatever short interest remains.
There is no meaningful institutional floor to speak of. The three largest reported holders are Fiber Food Systems (5.5%), Armistice Capital (3.3%), and Streeterville Capital (2.2%), with Vanguard and Geode holding token positions. Insider buying visible in the data is stale — the most recent trades were modest purchases by CEO Michael DePasquale and Chief Legal Officer James Sullivan back in mid-2025 at prices well below the current post-split equivalent. Those purchases carry little informational weight at this juncture.
Prior earnings reactions compound the caution. The most recent print, released March 31, sent the stock down 12% the next day. The one before it produced a 2.8% gain but gave it all back within five days. Neither reaction looks like a market that rewards this company for delivering results. With the 10-K still delayed and the next earnings date set for May 15, investors have limited tools to assess the fundamental picture before then.
The short score has ticked up to 52 from 44 two weeks ago — not alarming in absolute terms, but directionally worth tracking as the compliance situation develops. The EPS surprise factor score is a bright spot at the 91st percentile, suggesting the company has historically beaten consensus estimates. Whether that history carries any relevance against a backdrop of compliance notices and a delayed annual report is the question to watch between now and the May 15 event.
See the live data behind this article on ORTEX.
Open BKYI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
